VivoSeq
Other

Postsurgical Pain Management

1

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Postsurgical Pain Management is an early-stage landscape with 1 program across 1 company. The most active players are Shanghai Hengrui Pharmaceutical Co., Ltd.. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 31

Pharmacologic Pain Management

University of California, San Francisco

Approved
No programs

Analysis

Trial Status

10

clinical trials

Unknown status2 · 20%
Terminated2 · 20%
Completed2 · 20%
Not yet recruiting2 · 20%
Recruiting1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

A Phase Ⅱ/Ⅲ Study of HRS-2129 for Postsurgical Pain Management in Abdominal Surgery
Recruiting·SShandong Suncadia Medicine Co., Ltd.·Phase 2/3·NCT07185594·360 enrolled
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management
Active, not recruiting·Shanghai Hengrui Pharmaceutical Co., Ltd. logoShanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT05561309·89 enrolled
Phase 2/3 Study of TLC590 for Postsurgical Pain Management
Not yet recruiting·TTaiwan Liposome Company·Phase 2/3·NCT05161637·415 enrolled
An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service
Not yet recruiting·UUniversity of California, San Francisco·Phase 3·NCT07296770·126 enrolled
A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy
Completed·TTaiwan Liposome Company·Phase 2·NCT03838133·150 enrolled
Phase I/II Dose-escalation Study to Evaluate Safety, PK and Efficacy of TLC590 for Postsurgical Pain Management
Completed·TTaiwan Liposome Company·Phase 1/2·NCT03591146·65 enrolled
A Trial of SHR0410 Injection in Postsurgical Pain Management
Terminated·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT05394402·31 enrolled
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management in TKA
Terminated·Shanghai Hengrui Pharmaceutical Co., Ltd. logoShanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT06509958·15 enrolled
A Trial of HR021618 in Postsurgical Pain Management
Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT04699175·108 enrolled
Phase Ⅱ Study of Intercostal Nerve Block With HR18034 for Postsurgical Pain Management
Unknown status·Shanghai Hengrui Pharmaceutical Co., Ltd. logoShanghai Hengrui Pharmaceutical Co., Ltd.·Phase 2·NCT05744674·96 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)